Phaseline

Companies › PYC Therapeutics

PYC Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Ophthalmology, Genitourinary; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VP-001
Oligonucleotide-peptide conjugate targeting PRPF31 mutation
PRPF31Phase 1Retinitis Pigmentosa 11Mar 2028
PYC-003
Peptide-phosphorodiamidate morpholino oligonucleotide conjugate targeting PKD1
PKD1Phase 1Autosomal Dominant Polycystic Kidney Disease (ADPKD)Nov 2028
PYC-001
Peptide-phosphorodiamidate morpholino oligonucleotide (PMO) targeting OPA1
OPA1Phase 1OPA1 Gene MutationOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06852963VP-001Phase 1Retinitis Pigmentosa 11OphthalmologyMar 2028
NCT06714006PYC-003Phase 1Autosomal Dominant Polycystic Kidney Disease (ADPKD)GenitourinaryNov 2028
NCT06461286PYC-001Phase 1OPA1 Gene MutationOphthalmologyOct 2029
NCT06970106PYC-001Phase 1OPA1 Gene MutationOphthalmologyOct 2029

Targets

OPA1 (1) PKD1 (1) PRPF31 (1)

Companies with the same targets

Stealth BioTherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.